1. Academic Validation
  2. Cytotoxicity of phosphoramidate, bis-amidate and cycloSal prodrug metabolites against tumour and normal cells

Cytotoxicity of phosphoramidate, bis-amidate and cycloSal prodrug metabolites against tumour and normal cells

  • RSC Med Chem. 2024 Apr 18;15(6):1973-1981. doi: 10.1039/d4md00115j.
Rebecca E Farrell 1 Harrison Steele 1 Ryan J Middleton 2 Danielle Skropeta 1 Guo-Jun Liu 2 3
Affiliations

Affiliations

  • 1 School of Chemistry & Molecular Bioscience and Molecular Horizons, Faculty of Science, Medicine and Health, University of Wollongong Wollongong NSW 2522 Australia [email protected].
  • 2 Australian Nuclear Science and Technology Organisation Lucas Heights NSW 2234 Australia [email protected].
  • 3 Discipline of Medical Imaging Sciences, Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney Sydney NSW 2050 Australia.
Abstract

Phosphonate and phosphate prodrugs are integral to enhancing drug permeability, but the potential toxicity of their metabolites requires careful consideration. This study evaluates the impact of widely used phosphoramidate, bis-amidate, and cycloSal phosph(on)ate prodrug metabolites on BxPC3 pancreatic Cancer cells, GL261-Luc glioblastoma cells, and primary cultured mouse astrocytes. 1-Naphthol and 2-naphthol demonstrated the greatest toxicity. Notably, 2-naphthol exhibited an ED50 of 21 μM on BxPC3 cells, surpassing 1-naphthol with an ED50 of 82 μM. Real-time xCELLigence experiments revealed notable activity for both metabolites at a low concentration of 16 μM. On primary cultured mouse astrocyte cells, all prodrugs exhibited reduced viability at 128 to 256 μM after only 4 hours of exposure. A cell-type-dependent sensitivity to phosph(on)ate prodrug metabolites was evident, with normal cells showing greater susceptibility than corresponding tumour cells. The results suggest it is essential to consider the potential cytotoxicity of phosph(on)ate prodrugs in the drug design and evaluation process.

Figures